Wu Juan, Li Yuan-Yuan, Hu Jin-Hua, Jia Lin, Shi Ming, Meng Fan-Ping, Li Juan, Zhao Juan, Wang Fu-Sheng, Meng Qing-Hua
Department of Infectious Diseases, 302 Military Hospital of China - Peking University Teaching Hospital, Beijing, China.
Medical Center for Liver Failure, Beijing 302 Hospital, Beijing, China.
Hepatol Res. 2018 Feb;48(2):153-164. doi: 10.1111/hepr.12909. Epub 2017 Jun 4.
To determine the differential characteristics and prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) detected using Asian Pacific Association for the Study of the Liver (APASL) criteria and then classified using European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) criteria.
We retrospectively reviewed 316 HBV-related APASL ACLF patients treated at Beijing 302 Hospital or Beijing You'An Hospital (both Beijing, China) between February 2015 and February 2016. Clinical characteristics and mortality rates were compared among patients with different EASL-CLIF ACLF severity grades (no ACLF, and ACLF grades 1-3).
According to the EASL-CLIF criteria, 138 patients had no ACLF, 123 had ACLF at enrollment, and 55 developed ACLF during hospitalization. Both 28-day and 90-day transplant-free mortality were dramatically lower in patients without EASL-CLIF ACLF (0.7% and 5.1%, respectively) than in patients with EASL-CLIF ACLF (40.7% and 63.2%, respectively; both P < 0.001). Liver failure rates were similar in patients with and without EASL-CLIF ACLF, but extrahepatic organ failure was rare in patients without EASL-CLIF ACLF. Baseline serum creatinine, new bacterial infection and new acute kidney injury during hospitalization, maximum rising rates of CLIF-C ACLF score, and Model for End-stage Liver Disease score were independent predictors of EASL-CLIF ACLF after enrollment.
The EASL-CLIF ACLF classification can accurately prognosticate the short-term mortality of patients with HBV-related APASL ACLF. It can also distinguish distinct clinical characteristics and prognoses in patients with and without EASL-CLIF ACLF.
确定采用亚太肝病研究学会(APASL)标准检测出的乙型肝炎病毒(HBV)相关慢加急性肝衰竭(ACLF)患者的差异特征及预后情况,然后使用欧洲肝脏研究学会-慢性肝衰竭(EASL-CLIF)标准进行分类。
我们回顾性分析了2015年2月至2016年2月期间在北京302医院或北京佑安医院(均位于中国北京)接受治疗的316例HBV相关的APASL ACLF患者。比较了不同EASL-CLIF ACLF严重程度分级(无ACLF以及ACLF 1-3级)患者的临床特征和死亡率。
根据EASL-CLIF标准,138例患者无ACLF,123例患者入院时患有ACLF,55例患者在住院期间出现ACLF。无EASL-CLIF ACLF的患者28天和90天无移植死亡率(分别为0.7%和5.1%)显著低于有EASL-CLIF ACLF的患者(分别为40.7%和63.2%;P均<0.001)。有和无EASL-CLIF ACLF的患者肝衰竭发生率相似,但无EASL-CLIF ACLF的患者肝外器官衰竭少见。基线血清肌酐、住院期间新发细菌感染和新发急性肾损伤、CLIF-C ACLF评分的最大上升率以及终末期肝病模型评分是入院后EASL-CLIF ACLF的独立预测因素。
EASL-CLIF ACLF分类可准确预测HBV相关APASL ACLF患者的短期死亡率。它还能区分有和无EASL-CLIF ACLF患者的不同临床特征及预后。